Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263784 | 0.91 | — | — | |
| Propionic Acid SCHEMBL23467114 | 0.80 | FFAR3 (0.43) | ALDH1A1POLBCA1CA2SMN1; SMN2 | |
| SCHEMBL3181863 | 0.74 | ALDH1A1 (0.43) | ALDH1A1POLBHDAC2CA1CA2 | |
| SCHEMBL28941963 | 0.73 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL12350124 | 0.72 | TDP1 (0.36) | ALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL18026348 | 0.72 | ALDH1A1 (0.47) | ALDH1A1POLBHDAC2CA1CA2 | |
| SCHEMBL18893579 | 0.71 | POLB (0.37) | ALDH1A1POLBHDAC2CA1CA2 | |
| SCHEMBL19994668 | 0.71 | POLB (0.37) | ALDH1A1POLBHDAC2CA1CA2 | |
| SCHEMBL3318249 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1POLBHDAC2CA1CA2 | |
| SCHEMBL29261236 | 0.71 | POLB (0.40) | ALDH1A1POLBSMN1; SMN2NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546452-B2 | S1P3 receptor antagonist | TOA EIYO LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1935874-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | S1PR3, S1PR5, GPR3 | ALDH1A1 3155/4885POLB 4492/4885HDAC2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.